Angelman syndrome - Market Insights, Epidemiology and Market Forecast-2028
DelveInsight’s ‘Angelman syndrome - Market Insights, Epidemiology and Market Forecast-2028’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Angelman syndrome in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Angelman syndrome from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
Study Period: 2017-2028
Angelman syndrome - Disease Understanding and Treatment Algorithm
According to NORD (National Organization of Rare Disorders), Angelman syndrome is a rare genetic and neurological disorder characterized by severe developmental delays and learning disabilities, absence or near absence of speech, inability to coordinate voluntary movements (ataxia), tremulousness with jerky movements of the arms and legs, a distinctive behavioral pattern characterized by a happy disposition and unprovoked episodes of laughter and smiling, people with Angelman syndrome are usually happy and affectionate and may laugh often and at inappropriate times, affected people may also have epilepsy, is often associated with low levels of pigment in skin, hair and eyes.
Individuals affected with the syndrome unable to speak, many gradually learn to communicate through other means such as gesturing. In addition, children may have enough receptive language ability to understand simple forms of language communication. Additional symptoms may occur including seizures, sleep disorders and feeding difficulties. Some children with Angelman syndrome may have distinctive facial features but most facial features reflect the normal parental traits. Angelman syndrome is caused by deletion or abnormal expression of the UBE3A gene. Angelman syndrome occurs when only one copy of the gene is active in certain areas of the brain.
The DelveInsight Angelman syndrome market report gives the thorough understanding of the Angelman syndrome by including details such as disease definition, cause, signs and symptoms, complications, genetics, and diagnostic trends. It also provides treatment algorithms and treatment guidelines for Angelman syndrome in the US, Europe, and Japan.
Angelman syndrome Epidemiology
The Angelman syndrome epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report is segmented by Total Prevalent Cases of Angelman syndrome, Live Birth Cases of Angelman syndrome, Adult Prevalent Cases of Angelman syndrome, Diagnosed Prevalent Cases of Angelman syndrome, Angelman syndrome cases by Mutation Types, Angelman syndrome associated Clinical Manifestations.
According to DelveInsight, the prevalent cases of Angelman syndrome was 58,351 cases in 2017 in 7 MM and, is expected to increase at a CAGR of XX% during the study period i.e., 2017-2028. Among 7MM, United States account for highest prevalent cases of Angelman syndrome with 21,966 prevalent cases in 2017. This trend is expected to increase during the study period.
Angelman syndrome Drug Chapters
This segment of the Angelman syndrome report encloses the detailed analysis of marketed drugs and late stage (Phase-III) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases. This report includes detailed chapters of promising upcoming therapies.
Angelman syndrome Market Outlook
The Angelman syndrome market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
Angelman syndrome market is expected to grow during the forecasted period of 2019-2028 at a CAGR of XX% owing to the launch of few drugs (presently in Phase III and Phase II). Angelman syndrome therapeutics market has seen a 7MM sales of USD 274.8 Million in 2017.
Angelman syndrome Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Angelman syndrome Report Insights
• Patient Population
• Therapeutic Approaches
• Pipeline Analysis
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies
Angelman syndrome Report Key Strengths
• 10 Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition
Angelman syndrome Assessment
• Current Treatment Practices
• Unmet Needs
• Detailed Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers
• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Angelman syndrome market
• Organize sales and marketing efforts by identifying the best opportunities for Angelman syndrome market
• To understand the future market competition in the Angelman syndrome market.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook